Ahead of cru­cial PhII read­out, Sh­iono­gi lines up an op­tion to buy out biotech part­ner and its non-amy­loid Alzheimer's drug

With the make-or-break re­sults that will prove lit­tle Tetra right — or wrong — about its Alzheimer’s drug just around the cor­ner, part­ner Sh­iono­gi is putting it­self in a po­si­tion to act quick­ly should the Phase II tri­al come back pos­i­tive.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER